Understand the source comparison
LL-37 vs VIP: Full Mechanism Comparison
The table below compares LL-37 and VIP across mechanism, receptor targets, primary applications, stability constraints, and research contexts where each peptide demonstrates clear advantages. This is not a ranking. It's a functional differentiation tool. | Pep
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares LL-37 and VIP across mechanism, receptor targets, primary applications, stability constraints, and research contexts where each peptide demonstrates clear advantages. This is not a ranking. It's a functional differentiation tool.
- | Peptide | Primary Mechanism | Receptor/Target | Half-Life | Primary Research Applications | Stability Constraints | Professional Assessment ||—|—|—|—|—|—|| LL-37 | Membrane disruption via electrostatic binding; chemoattractant for innate immune cells | FPRL1, direct LPS binding, bacterial membrane phospholipids | ~6 hours in vivo (protected by serum proteins) | Antimicrobial efficacy, wound healing, innate immunity, sepsis models, biofilm disruption | Degrades rapidly in protease-rich environments; avoid benzyl alcohol in reconstitution | Best choice for pathogen-response studies and barrier surface research. Direct microbial action with secondary immunomodulation || VIP | NF-κB inhibition, cAMP elevation via VPAC receptors | VPAC1, VPAC2 (G-protein-coupled receptors) | 1–2 minutes in circulation (DPP-IV cleavage) | Autoimmune disease models, neuroprotection, IBD, asthma, septic shock, Th17/Treg balance studies | Oxidation-prone (methionine residues); requires −80°C storage post-reco